Lucira Health, Inc. (NASDAQ:LHDX – Get Rating)'s share price dropped 16.7% on Wednesday . The stock traded as low as $0.11 and last traded at $0.13. 1,862,216 shares were traded during trading, a decline of 94% from the average daily volume of 29,320,967 shares. The stock had previously closed at $0.15.

Lucira Health Stock Down 16.7 %

The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $5.01 million, a PE ratio of -0.03 and a beta of 3.75. The business has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.45.

Institutional Trading of Lucira Health

Large investors have recently added to or reduced their stakes in the stock. EPIQ Capital Group LLC boosted its position in shares of Lucira Health by 0.7% during the 3rd quarter. EPIQ Capital Group LLC now owns 13,737,370 shares of the company's stock valued at $14,562,000 after acquiring an additional 97,502 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Lucira Health by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 631,767 shares of the company's stock valued at $2,256,000 after purchasing an additional 119,929 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Lucira Health in the 3rd quarter valued at approximately $339,000. BlackRock Inc. increased its holdings in shares of Lucira Health by 18.8% during the 1st quarter. BlackRock Inc. now owns 51,468 shares of the company's stock worth $183,000 after buying an additional 8,131 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Lucira Health during the 2nd quarter valued at approximately $78,000. 57.02% of the stock is currently owned by hedge funds and other institutional investors.

Lucira Health Company Profile

(Get Rating)

Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

See Also

• Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
• ASML Reports Massive Growth, Management Points To Sluggish 2023
• Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
• Mullen Automotive: Is The Bloom Off The Rose?
• Diversified Abbott Laboratories Could Reverse And Move Higher
• Okta Reversal In Progress While Catalysts Approach

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.